3.35 USD
↘ 0.12 (3.46%)AT CLOSE (11:59 AM EDT)
Eledon Pharmaceuticals, Inc. Common Stock
ELDNNASDAQ • USD
3.41
↗ 0.06 (1.91%)
POST MARKET (AS OF 07:44 PM EDT)
Post Market
AS OF 07:44 PM EDT
3.41
↗ 0.06 (1.91%)
Market: CLOSED
Shares of Eledon Pharmaceuticals, Inc. Common Stock (ELDN) are trading at $3.34. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On the valuation front, ELDN trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Aug 26, 2026.
Open?$3.47
High?$3.50
Low?$3.34
Prev. Close?$3.47
Volume?820.4K
Avg. Volume?923.9K
VWAP?$3.37
Rel. Volume?0.89x
Bid / Ask
Bid?$3.33 × 300
Ask?$3.40 × 700
Spread?$0.07
Midpoint?$3.37
Valuation & Ratios
Market Cap?272.2M
Shares Out?81.3M
Float?77.2M
Float %?100.0%
P/E Ratio?N/A
P/B Ratio?8.25
EPS?-$1.19
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
Themes
Address
19800 MACARTHUR BLVD.
IRVINE, CA 92612
Phone: 949-238-8090
IRVINE, CA 92612
Phone: 949-238-8090
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?50
Short Sent.?34
Piotroski F-Score?0/9Weak
Altman Z-Score?-3.55Distress
Confidence?59%Low
Short InterestHigh
Short % of Float?8.15%Elevated
Short Interest?6.3M
Days to Cover?6.9
Free Float77.2M
Avg Daily Volume915.1K
Settlement Date2026-08-14
Financial Health
Current Ratio?7.90Strong
Quick Ratio?7.90Strong
Cash Ratio?0.58Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?8.25HIGH▾
Peers100
S&P23
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-3.1CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-292.1%WEAK▾
S&P3
ROA?-76.5%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-73857000
Enterprise Value?$265.4M
Fundamentals ratios updated end of day